Current Colorectal Cancer Reports

, Volume 3, Issue 1, pp 16–23 | Cite as

Colorectal cancer prevention: Diet, drugs, or nothing



Colorectal cancer (CRC), one of the leading causes of cancer death worldwide, is now considered the most preventable malignancy. Although an estimated 145,290 Americans were diagnosed and approximately 56,290 died of the disease, CRC death could be prevented in 28,145 cases if the American Cancer Society’s screening recommendations were followed. By virtue of endoscopic and imaging accessibility of the colorectum, along with its well-characterized pathogenesis, CRC prevention and early detection have become a reality that could significantly diminish death and suffering from cancer. Unfortunately, widespread application of current screening technologies has been difficult; progress continues as visualization of and access to the colorectum enable researchers to evaluate the activity of dietary changes, nutritional supplementation, and chemoprevention agents on genetic, molecular, and histologic colorectal carcinogenesis.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Boyle P, Langman JS: ABC of colorectal cancer: epidemiology. BMJ 2000, 321:805–808.PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10–30.PubMedGoogle Scholar
  3. 3.
    Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74–108.PubMedCrossRefGoogle Scholar
  4. 4.
    Fearon ER, Vogelstein B: A genetic model for colorectal tum origenesis. Cell 1990, 61:759–767.PubMedCrossRefGoogle Scholar
  5. 5.
    Vogelstein B, Fearon ER, Hamilton SR, et al.: Genetic alterations during colorectal-tum or development. New Engl J Med 1988, 319:525–532.PubMedCrossRefGoogle Scholar
  6. 6.
    Fearon ER: Human cancer syndromes: clues to the origin and nature of cancer. Science 1997, 278:1043–1050.PubMedCrossRefGoogle Scholar
  7. 7.
    Kinzler KW, Nilbert MC, Su LK, et al.: Identification of FAP locus genes from chromosome 5q21. Science 1991, 253:661–665.PubMedCrossRefGoogle Scholar
  8. 8.
    Kinzler KW, Nilbert MC, Vogelstein B, et al.: Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 1991, 251:1366–1370.PubMedCrossRefGoogle Scholar
  9. 9.
    Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996, 87:159–170.PubMedCrossRefGoogle Scholar
  10. 10.
    Day DW: The adenom a-carcinoma sequence. Scand J Gastroenterol Suppl 1984, 104:99–107.PubMedGoogle Scholar
  11. 11.
    Morson BC: Evolution of cancer of the colon and rectum. Proc Inst Med Chic 1974, 30:145–148.PubMedGoogle Scholar
  12. 12.
    Hamilton SR: Origin of colorectal cancers in hyperplastic polyps and serrated adenomas: another truism bites the dust. J Natl Cancer Inst 2001, 93:1282–1283.PubMedCrossRefGoogle Scholar
  13. 13.
    Hawk ET, Levin B: Colorectal cancer prevention. J Clin Oncol 2005, 23:378–391.PubMedCrossRefGoogle Scholar
  14. 14.
    Sporn MB: Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976, 36:2699–2702.PubMedGoogle Scholar
  15. 15.
    Forman MR, Hursting SD, Umar A, Barrett JC: Nutrition and cancer prevention: a multidisciplinary perspective on human trials. Annu Rev Nutr 2004, 24:223–254.PubMedCrossRefGoogle Scholar
  16. 16.
    Nakaji S, Ishiguro S, Iwane S, et al.: The prevention of colon carcinogenesis in rats by dietary cellulose is greater than the promotive effect of dietary lard as assessed by repeated endoscopic observation. J Nutr 2004, 134:935–939.PubMedGoogle Scholar
  17. 17.
    Alberts DS, Martinez ME, Roe DJ, et al.: Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. N Engl J Med 2000, 342:1156–1162.PubMedCrossRefGoogle Scholar
  18. 18.
    Bonithon-Kopp C, Kronborg O, Giacosa A, et al.: Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organization Study Group. Lancet 2000, 356:1300–1306.PubMedCrossRefGoogle Scholar
  19. 19.
    Schatzkin A, Lanza E, Corle D, Lance P, et al.: Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000, 342:1149–1155.PubMedCrossRefGoogle Scholar
  20. 20.
    Bingham S: The fibre-folate debate in colo-rectal cancer. Proc Nutr Soc 2006, 65:19–23.PubMedCrossRefGoogle Scholar
  21. 21.
    Baron JA, Beach M, Mandel JS, et al.: Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999, 340:101–107.PubMedCrossRefGoogle Scholar
  22. 22.
    Flood A, Peters U, Chatterjee N, et al.: Calcium from diet and supplements is associated with reduced risk of colorectal cancer in a prospective cohort of women. Cancer Epidemiol Biomarkers Prev 2005, 14:126–132.PubMedGoogle Scholar
  23. 23.
    Wactawski-Wende J, Kotchen JM, Anderson GL, et al.: Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006, 354:684–696.PubMedCrossRefGoogle Scholar
  24. 24.
    Giovannucci E: The epidemiology of vitamin D and colorectal cancer: recent findings. Curr Opin Gastroenterol 2006, 22:24–29.PubMedCrossRefGoogle Scholar
  25. 25.
    McCullough ML, Robertson AS, Rodriguez C, et al.: Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States). Cancer Causes Control 2003, 14:1–12.PubMedCrossRefGoogle Scholar
  26. 26.
    Cross HS, Kallay E, Lechner D, et al.: Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. J Nutr 2004, 134:1207S–1212S.PubMedGoogle Scholar
  27. 27.
    Garland CF, Garland FC, Gorham ED: Can colon cancer incidence and death rates be reduced with calcium and vitamin D? Am J Clin Nutr 1991, 54(1 Suppl):193S–201S.PubMedGoogle Scholar
  28. 28.
    Harris DM, Go VL: Vitamin D and colon carcinogenesis. J Nutr 2004, 134(12 Suppl):3463S–3471S.PubMedGoogle Scholar
  29. 29.
    Lamprecht SA, Lipkin M: Cellular mechanisms of calcium and vitamin D in the inhibition of colorectal carcinogenesis. Ann N Y Acad Sci 2001, 952:73–87.PubMedCrossRefGoogle Scholar
  30. 30.
    Sun CL, Yuan JM, Koh WP, Yu MC: Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis 2006, 27:1301–1309.PubMedCrossRefGoogle Scholar
  31. 31.
    Beltz LA, Bayer DK, Moss AL, Simet IM: Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 2006, 6:389–406.PubMedCrossRefGoogle Scholar
  32. 32.
    Suganuma M, Ohkura Y, Okabe S, Fujiki H: Combination cancer chemoprevention with green tea extract and sulindac shown in intestinal tum or formation in Min mice. J Cancer Res Clin Oncol 2001, 127:69–72.PubMedCrossRefGoogle Scholar
  33. 33.
    Caderni G, De Filippo C, Luceri C, et al.: Effects of black tea, green tea and wine extracts on intestinal carcinogenesis induced by azoxymethane in F344 rats. Carcinogenesis 2000, 21:1965–1969.PubMedCrossRefGoogle Scholar
  34. 34.
    Jia X, Han C: Effects of green tea on colonic aberrant crypt foci and proliferative indexes in rats. Nutr Cancer 2001, 39:239–243.PubMedCrossRefGoogle Scholar
  35. 35.
    Kelloff GJ, Crowell JA, Steele VE, et al.: Progress in cancer chemoprevention. Ann N Y Acad Sci 1999, 889:1–13.PubMedCrossRefGoogle Scholar
  36. 36.
    Schut HA, Yao R: Tea as a potential chemopreventive agent in PhIP carcinogenesis: effects of green tea and black tea on PhIP-DNA adduct formation in female F-344 rats. Nutr Cancer 2000, 36:52–58.PubMedCrossRefGoogle Scholar
  37. 37.
    Umar A, Viner JL, Richmond E, et al.: Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol 2002, 7:2–26.PubMedGoogle Scholar
  38. 38.
    Farah AE, Rosenberg F: Potential therapeutic applications of aspirin and other cyclo-oxygenase inhibitors. Br J Clin Pharmacol 1980, 10(Suppl 2):261S–278S.PubMedGoogle Scholar
  39. 39.
    Gasic GJ, Gasic TB, Murphy S: Anti-metastatic effect of aspirin. Lancet 1972, 2:932–933.PubMedCrossRefGoogle Scholar
  40. 40.
    Henschke UK, Luande GJ, Choppala JD: Aspirin for reducing cancer metastases? J Natl Med Assoc 1977, 69:581–584.PubMedGoogle Scholar
  41. 41.
    Seed MP, Freemantle CN, Alam CA, et al.: Apoptosis induction and inhibition of colon-26 tumor growth and angiogenesis: findings on COX-1 and COX-2 inhibitors in vitro and in vivo and topical diclofenac in hyaluronan. Adv Exp Med Biol 1997, 433:339–342.PubMedGoogle Scholar
  42. 42.
    Giardiello FM, Hamilton SR, Krush AJ, et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 328:1313–1316.PubMedCrossRefGoogle Scholar
  43. 43.
    Labayle D, Fischer D, Vielh P, et al.: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991, 101:635–639.PubMedGoogle Scholar
  44. 44.
    Baron JA, Cole BF, Sandler RS, et al.: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003, 348:891–899.PubMedCrossRefGoogle Scholar
  45. 45.
    Benamouzig R, Deyra J, Martin A, et al.: Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003, 125:328–336.PubMedCrossRefGoogle Scholar
  46. 46.
    Sandler RS, Halabi S, Baron JA, et al.: A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003, 348:883–890.PubMedCrossRefGoogle Scholar
  47. 47.
    Logan FL, Muir KR, Graindge MJ, et al.: Aspirin for the prevention of recurrent colorectal adenomas—results of the UKCAP trial. DDW 2006 [abstract 438]. Presented at the Potsdamer Gastroenterologisches Seminar. Munich, Germany; September 1–3, 2006.Google Scholar
  48. 48.
    Arber N, Eagle CJ, Spicak J, et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885–895.PubMedCrossRefGoogle Scholar
  49. 49.
    Bertagnolli MM, Eagle CJ, Zauber AG, et al.: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355:873–884.PubMedCrossRefGoogle Scholar
  50. 50.
    Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071–1080.PubMedCrossRefGoogle Scholar
  51. 51.
    Tempero MA, Nishioka K, Knott K, Zetterman RK: Chem oprevention of mouse colon tumors with difluoromethylornithine during and after carcinogen treatment. Cancer Res 1989, 49:5793–5797.PubMedGoogle Scholar
  52. 52.
    Thompson HJ, Meeker LD, Herbst EJ, et al.: Effect of concentration of D,L-2-difluoromethylornithine on murine mammary carcinogenesis. Cancer Res 1985, 45:1170–1173.PubMedGoogle Scholar
  53. 53.
    Meyskens FL Jr, Gerner EW: Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer. J Cell Biochem Suppl 1995, 22:126–131.PubMedCrossRefGoogle Scholar
  54. 54.
    Lao CD, Backoff P, Shotland LI, et al.: Irreversible ototoxicity associated with difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 2004, 13:1250–1252.PubMedGoogle Scholar
  55. 55.
    Harari PM, Huang SM: Combining EGFR inhibitors with radiation or chem otherapy: will preclinical studies predict clinical results? Int J Radiat Oncol Biol Phys 2004, 58:976–983.PubMedCrossRefGoogle Scholar
  56. 56.
    Kelloff GJ, Fay JR, Steele VE, et al.: Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1996, 5:657–666.PubMedGoogle Scholar
  57. 57.
    Tortora G, Bianco R, Daniele G: Strategies for multiple signaling inhibition. J Chemother 2004, 16(Suppl 4):41–43.PubMedGoogle Scholar
  58. 58.
    Viloria-Petit AM, Kerbel RS: Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 2004, 58:914–926.PubMedCrossRefGoogle Scholar
  59. 59.
    Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999, 82:241–250.PubMedCrossRefGoogle Scholar
  60. 60.
    Torrance CJ, Jackson PE, Montgomery E, et al.: Combinatorial chemoprevention of intestinal neoplasia. Nat Med 2000, 6:1024–1028.PubMedCrossRefGoogle Scholar
  61. 61.
    Roberts RB, Min L, Washington MK, et al.: Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tum origenesis. Proc Natl Acad Sci U S A 2002, 99:1521–1526.PubMedCrossRefGoogle Scholar
  62. 62.
    Sipples R: Common side effects of anti-EGFR therapy: acneform rash. Semin Oncol Nurs 2006, 22(Suppl 1):28–34.PubMedCrossRefGoogle Scholar
  63. 63.
    Swan J, Breen N, Coates RJ, et al.: Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 2003, 97:1528–1540.PubMedCrossRefGoogle Scholar
  64. 64.
    Rembold CM: Number needed to screen: development of a statistic for disease screening. BMJ 1998, 317:307–312.PubMedGoogle Scholar
  65. 65.
    Smith RA, Mettlin CJ, Davis KJ, Eyre H: American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2000, 50:34–49.PubMedGoogle Scholar
  66. 66.
    Towler BP, Irwig L, Glasziou P, et al.: Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database Syst Rev 2000, 2:CD0001216.Google Scholar
  67. 67.
    Winawer SJ, Fletcher RH, Miller L, et al.: Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997, 112:594–642.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Gastrointestinal and Other Cancers Research Group, Division of Cancer PreventionNational Cancer InstituteBethesdaUSA

Personalised recommendations